In the Claims:

This listing of claims will replace all prior versions and listings of claims in this application.

1-17 (Canceled).

18 (Currently amended). A compound comprising affinity ligands wherein the compound is immobilized on a support matrix, and wherein the compound, together with the support matrix, is represented by the formula



wherein each Z is the same or different and is



wherein each X is independently selected from –NH- and diaminoalkane, diethylenetriamine or tris(aminoethyl)amine spacers linked to the triazine rings by amine groups,

each Y is the same or different affinity ligand linked to the appropriate triazine ring by an amine group; and

M is a support matrix.

19 (Previously presented). The compound according to claim 18, of the formula



20 (Previously presented). The compound according to claim 19, wherein either or each Z is Y.

21 (Previously presented). The compound according to claim 18, wherein each X independently represents a secondary amino group or a diaminoalkane.

22 (currently amended). The compound according to claim 18, wherein each Y is independently selected from optionally substituted aliphatic and aromatic primary amines.

23 (Previously presented). The compound according to claim 18, of the formula



24 (Cancelled).

25 (Currently amended). A method for the synthesis of a compound comprising affinity ligands wherein the compound is immobilized on a support matrix, and wherein the compound, together with the support matrix, is represented by the formula



wherein each Z is the same or different and is



or –Y

wherein each X is independently selected from –NH- and diaminoalkane, diethylenetriamine or tris(aminoethyl)amine spacers linked to the triazine rings by amine groups;

each Y is the same or different affinity ligand linked to the appropriate triazine ring by an amine group; and

M is a support matrix;

wherein said method comprises the reaction of a compound of the formula



wherein each Z is the same or different and is



or –Y,

with an amine-containing support matrix.

26 (Cancelled).

27 (Previously presented). A library of compounds of the formula:



wherein each Z is the same or different and is



or –Y

wherein each X is independently selected from –NH- and diaminoalkane, diethylenetriamine or tris(aminoethyl)amine spacers linked to the triazine rings by amine groups;

each Y is the same or different affinity ligand linked to the appropriate triazine ring by an amine group; and

M is a support matrix.

28 (Previously presented). A method for the production of a library of compounds of the formula:



wherein each Z is the same or different and is



or –Y

wherein each X is independently selected from –NH- and diaminoalkane, diethylenetriamine or tris(aminoethyl)amine spacers linked to the triazine rings by amine groups

each Y is the same or different affinity ligand linked to the appropriate triazine ring by an amine group; and

M is a support matrix

wherein said method comprises the synthesis of intermediate structures, either singly or in multiples, dividing the structures into smaller portions, and carrying out appropriate subsequent reaction steps.

29 (Previously presented). A method for the separation, isolation, and/or purification of peptides and proteins from a preparation of biological or pharmaceutical compound wherein said method comprises the use of a compound of the formula



wherein each Z is the same or different and is



or –Y

wherein each X is independently selected from –NH- and diaminoalkanc, diethylenetriamine or tris(aminoethyl)amine spaccrs linked to the triazine rings by amine groups;

each Y is the same or different affinity ligand linked to the appropriate triazine ring by an amine group; and

M is a support matrix.

30 (Previously presented). The method, according to claim 29, which comprises subjecting a sample containing a protcinaceous matcrial to affinity chromatography using said compound.

31 (Previously presented). The process according to claim 30, wherein the proteinaceous material is an immunoglobulin or a subclass, fragment, precursor or derivative thereof, including fusion proteins, whether derived from natural or recombinant sources.

32 (Previously presented). The method according to claim 29, for the removal of contaminants, including toxic or pathogenic entities, from a preparation of biological or pharmaceutical compound.

33 (Previously presented). The library, according to claim 27, wherein the compounds are on a common support.

34 (Previously presented). The compound according to claim 18, which contains 2 or more triazine rings and 3 independently available Y groups.

35 (Previously presented). The compound according to claim 18, which contains 3 or more triazine rings and 4 independently available Y groups.